Nicole Schreiber was appointed the Senior Director of Clinical Strategy at Convergent Therapeutics in August 2021. Prior to joining Convergent, she worked as an Associate Director with the Prostate Cancer Clinical Trials Consortium (PCCTC) to develop PCCTC’s Correlative Science Program. Ms. Schreiber managed the translational research efforts of a portfolio of 22 multicenter clinical trials, forming strategic partnerships with academic, pharmaceutical, and biotechnology companies to advance drug and biomarker development. Before her role at PCCTC, she was a Project Manager at Memorial Sloan Kettering Cancer Center where she built the Blood-Based Biomarker Team under Dr. Howard Scher in the Genitourinary Oncology Service. Ms. Schreiber was a lead contributor to the analytical and clinical validation of the Oncotype DX AR-V7 Nucleus Detect® test for metastatic prostate cancer, leading to the test’s commercialization in the United States.

Ms. Schreiber graduated cum laude from the University of Maryland at College Park with a Bachelor of Arts degree in English Language and Literature and an Independent Study in Environmental Microbiology.